3.15
+0.105(+3.45%)
Currency In USD
| Previous Close | 3.04 |
| Open | 3.05 |
| Day High | 3.21 |
| Day Low | 3.02 |
| 52-Week High | 5.31 |
| 52-Week Low | 1.84 |
| Volume | 782,493 |
| Average Volume | 1.17M |
| Market Cap | 160.73M |
| PE | -2.12 |
| EPS | -1.48 |
| Moving Average 50 Days | 2.82 |
| Moving Average 200 Days | 2.97 |
| Change | 0.11 |
If you invested $1000 in Achieve Life Sciences, Inc. (ACHV) 10 years ago, it would be worth $0.64 as of September 30, 2025 at a share price of $3.145. Whereas If you bought $1000 worth of Achieve Life Sciences, Inc. (ACHV) shares 5 years ago, it would be worth $375.75 as of September 30, 2025 at a share price of $3.145.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline’s Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD
GlobeNewswire Inc.
Sep 22, 2025 12:30 PM GMT
New data address critical treatment gap for millions of Americans with COPD who face unique smoking cessation challengesSEATTLE and VANCOUVER, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-s
Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer
GlobeNewswire Inc.
Sep 18, 2025 12:30 PM GMT
Donnelly brings more than 25 years of biopharmaceutical expertise in CMC and regulatory operationsSEATTLE and VANCOUVER, British Columbia, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharma
Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer
GlobeNewswire Inc.
Sep 11, 2025 9:01 PM GMT
SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treat